Last checked at 
The pharmaceutical company reported a pretax loss of
Cash at the period end dropped to
The pharmaceutical company said that it had positive feedback on the two phase III MED2002 trials in the clinical programme, and the commercial out-licensing discussions for the gel were at an "advanced stage".
"2018 has started well particularly with the progress of our Phase III clinical programme for MED2002, our breakthrough erectile dysfunction gel. The positive interim data announced yesterday from our pharmacokinetic study indicates that we will be able to include at least two higher strength doses of MED2002 in our Phase III clinical studies along with the dose used in our earlier Phase II study thereby offering the potential for improved efficacy," said Chief Executive James Barder.
Shares in the company were down 7.7% at
